Please login to the form below

Not currently logged in
Email:
Password:

Ethicon BLA for surgical drug-device combo

Johnson & Johnson's Ethicon subsidiary has submitted a Biologic License Application to the US FDA for a device that also contains prescription drugs
Reflecting a growing trend toward the development and marketing of devices that also contain prescription drugs, Johnson & Johnson's (J&J) Ethicon subsidiary has submitted a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for the Fibrin Pad, which combines biomaterials and the plasma-derived biologics Human Fibrinogen and Human Thrombin to reduce bleeding during surgery.

The submission "is an excellent example of convergence within Johnson & Johnson, bringing together our medical device and pharmaceutical expertise," said Dr Jim Hart, vice president medical affairs, Ethicon.

The pad is intended for use as an adjunct to homeostasis when surgical methods for controlling bleeding are ineffective or impractical. Specifically, the BLA seeks clearance for use of the pad during retroperitoneal, intra-abdominal, pelvic, and (non cardiac) thoracic surgery.

The marketing application centres around data from a randomised, controlled clinical study that tested the Fibrin Pad as an adjunct to hemostasis in soft tissue bleeding.

Ethicon licensed the fibrin sealant biologicals used in the product from Omrix Biopharmaceuticals, a company focused on biosurgical and passive immunotherapy products.

Omrix has estimated that there is a potential $400m global market opportunity for the Fibrin Pad. 

22nd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics